INM — InMed Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $3.61m
- $0.15m
- $4.60m
- 24
- 64
- 25
- 31
Annual cashflow statement for InMed Pharmaceuticals, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
R2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.94 | -10.2 | -18.6 | -7.95 | -7.68 |
| Depreciation | |||||
| Non-Cash Items | 1.17 | 0.836 | 5.9 | 1.03 | 0.839 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.286 | -0.544 | -3.07 | -0.566 | -0.369 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -7.37 | -9.79 | -15.6 | -7.28 | -6.99 |
| Capital Expenditures | -0.043 | -0.002 | -0.039 | -0.16 | -0.009 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 3.83 | 0 | -0.634 | -0.502 | 0 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 3.79 | -0.002 | -0.673 | -0.662 | -0.009 |
| Financing Cash Flow Items | -0.031 | -1.62 | -1.78 | -1.32 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.031 | 10.9 | 15.1 | 10.7 | 4.65 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.03 | 1.56 | -1.19 | 2.74 | -2.34 |